Increasing microbial resistance is creating a demand for new drugs, which is currently not matched by privately-funded research and development, making it all the more important to obtain protection with smart, cost effective IP strategies for novel inventions addressing the innovation void.
The repurposing of drugs can also be protected by patents, which requires experience and expertise in second-medical use claims to provide the best possible support.
Universities and research institutions, start-up companies and SMEs all benefit from the wide-ranging, commercially relevant experience of HGF’s anti-infectives IP team, who possess deep knowledge and understanding of the shifting patent laws that affect innovators in areas relating to anti-infective agents.
HGF’s specialist attorneys combine extensive legal, scientific and transactional expertise with in-house backgrounds to develop multijurisdictional IP protection strategies across antibiotics, antivirals, immunomodulators and vaccines, as well as diagnostic methods and technologies.
The anti-infectives team specialises in patent and trade mark protection, with targeted and industry-validated advice on drafting and prosecuting, including second medical use type claims and cross jurisdictional drafting of patent applications. Furthermore, the attorneys are highly accomplished across oppositions and appeals in biologics, small molecule drugs and diagnostic devices, freedom-to-operate analysis, in-and-out licensing and supplementary protection certificates (SPCs).
Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details
HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …Event details
HGF Partner and Patent Attorney Craig Thomson and Patent Director Dr Jennifer Bailey write an article for The Microbiome Times on ELIGO v SNIPR: a reflection on IP strategies in …Read article
One of the most often asked questions of patent attorneys is “when should we file?” Both timing and content of a first filing should be important strategic decisions. This is …Read article
Using SleepCogni as a case study, we look at some key ways that IP can help start-ups to develop their technology and secure investment. SleepCogni is a SleepTech start-up who …Read article
9th Microbiome R&D and Business Collaboration Forum: Europe will be held on 26th-27th October 2021 in Rotterdam, The Netherlands. The event is dedicated to exploring microbiome research and strategies for …Event details
Medical Technology Ireland Conference will be held on 20-21 October 2021 at the Galway Racecourse. Medical Technology Ireland Conference features presentations by leading international medical device experts with thought-provoking guest …Event details